MASM
TEVA icon

MH & Associates Securities Management’s Teva Pharmaceuticals TEVA Stock Holding History

MH & Associates Securities Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.28M Sell
96,958
-1,529
-2% -$50.9K 2.95% 14
2026
Q1 		$2.97M Sell
98,487
-40,244
-29% -$1.29M 2.59% 18
2025
Q4 		$4.33M Buy
+138,731
New +$3.42M 3.54% 4

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

MH & Associates Securities Management's TEVA Position: Q2 2026 in Review

MH & Associates Securities Management reduced its Teva Pharmaceuticals (TEVA) stake by 1.6% in Q2 2026, selling an estimated $50.9K and leaving 96,958 shares worth $3.28M. The position accounts for 2.95% of the portfolio, ranked #14.

MH & Associates Securities Management first reported a position in TEVA in Q4 2025 and has held it in 3 quarters since. The position peaked at $4.33M in Q4 2025. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • MH & Associates Securities Management held 96,958 shares of Teva Pharmaceuticals worth $3.28M as of Q2 2026.
  • MH & Associates Securities Management sold 1,529 Teva Pharmaceuticals shares in Q2 2026, an estimated $50.9K.
  • Teva Pharmaceuticals made up 2.95% of MH & Associates Securities Management's portfolio in Q2 2026, its #14 holding.
  • MH & Associates Securities Management first reported a position in Teva Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • MH & Associates Securities Management's Teva Pharmaceuticals position peaked at $4.33M in Q4 2025.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on MH & Associates Securities Management's 13F filing for Q2 2026, filed 28 Jul 2026.